| Title |
The new concepts on overcoming drug resistance in lung cancer
|
|---|---|
| Published in |
Drug Design, Development and Therapy, June 2014
|
| DOI | 10.2147/dddt.s60672 |
| Pubmed ID | |
| Authors |
Weisan Zhang, Ping Lei, Xifeng Dong, Cuiping Xu |
| Abstract |
Lung cancer is one of the most deadly diseases worldwide. The current first-line therapies include chemotherapy using epidermal growth factor receptor tyrosine kinase inhibitors and radiotherapies. With the current progress in identifying new molecular targets, acquired drug resistance stands as an obstacle for good prognosis. About half the patients receiving epidermal growth factor receptor-tyrosine kinase inhibitor treatments develop resistance. Although extensive studies have been applied to elucidate the underlying mechanisms, evidence is far from enough to establish a well-defined picture to correct resistance. In the review, we will discuss four different currently developed strategies that have the potential to overcome drug resistance in lung cancer therapies and facilitate prolonged anticancer effects of the first-line therapies. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Austria | 1 | 3% |
| Canada | 1 | 3% |
| Unknown | 33 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 19% |
| Student > Ph. D. Student | 6 | 17% |
| Researcher | 4 | 11% |
| Student > Postgraduate | 4 | 11% |
| Professor | 2 | 6% |
| Other | 6 | 17% |
| Unknown | 7 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 11 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 17% |
| Agricultural and Biological Sciences | 6 | 17% |
| Medicine and Dentistry | 5 | 14% |
| Immunology and Microbiology | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 6 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 June 2014.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#1,416
of 2,254 outputs
Outputs of similar age
#177,308
of 241,269 outputs
Outputs of similar age from Drug Design, Development and Therapy
#28
of 46 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,269 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.